The Year in Cardiovascularmedicine 2020: Arrhythmias

Harry J.G.M. Crijns; Frits Prinzen; Pier D. Lambiase; Prashanthan Sanders; Josep Brugada


Eur Heart J. 2021;42(5):499-507. 

In This Article

Abstract and Introduction


Graphical Abstract

Summary of the progress in arrhythmias in 2020. RACE4 and ALL-IN indicated that integrated nurse-led care improves outcomes in AF patients.[3,4] The same was reported for early rhythm control therapy[15] and cryoablation as initial AF treatment.[25,26] Subcutaneous ICD was non-inferior to classical transvenous ICD therapy in PRAETORIAN.[54] One mechanistic study showed that autoantibodies against misexpressed actin, keratin, and connexin-43 proteins create a blood-borne biomarker profile enhancing diagnosis of Brugada syndrome.[50] Another mechanistic study indicated that transseptal LV pacing yields similar improvement in contractility as His bundle pacing whilst being more easy to execute.[44] In PRE-DETERMINE a simple-to-use ECG risk score improved risk prediction in patients with ischemic heart disease possibly enhancing appropriate ICD therapy in high risk patients.[58]


The Year in Cardiovascular Medicine: Arrhythmias 2020 reviews the most relevant studies in the field of arrhythmias and pacing. The past year has shown a significant progress: landmark clinical trials in atrial fibrillation (AF) and implantable defibrillator (ICD) therapy, new guidelines, integrated care, life style and arrhythmias, His bundle pacing, risk prediction in sudden cardiac death, and advances in cardiogenetics.